2025
Short-term estradiol administration does not restore endothelin‐B receptor‐mediated vasodilation in postmenopausal women
Nuckols V, Shoemaker L, Kuczmarski A, Haigh K, McGinty S, Del Vecchio A, Schwab A, Edwards D, Taylor H, Wenner M. Short-term estradiol administration does not restore endothelin‐B receptor‐mediated vasodilation in postmenopausal women. AJP Heart And Circulatory Physiology 2025, 328: h327-h332. PMID: 39773019, PMCID: PMC12175985, DOI: 10.1152/ajpheart.00815.2024.Peer-Reviewed Original ResearchConceptsPostmenopausal womenExogenous estradiol administrationEndothelin B receptorEstradiol administrationPremenopausal womenLactated RingeHealthy postmenopausal womenYoung womenLaser Doppler flowmetryEndothelin-BVasodilatory responseTransdermal patchDoppler flowmetryCutaneous microcirculationVasodilationEstradiolAdministrationWomenReceptorsRingerBlockadeFlowmetry
2022
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials
Donnez J, Taylor HS, Stewart EA, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland JP, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. The Lancet 2022, 400: 896-907. PMID: 36116480, DOI: 10.1016/s0140-6736(22)01475-1.Peer-Reviewed Original ResearchConceptsHeavy menstrual bleedingPhase 3 trialSymptomatic uterine fibroidsMenstrual bleedingUterine fibroidsTherapy groupPlacebo groupOral gonadotropin-releasing hormone receptor antagonistResponse rateGonadotropin-releasing hormone receptor antagonistCommon adverse eventsFull analysis setHormone receptor antagonistDose of treatmentMasked treatmentPrimary endpointStudy drugAdverse eventsEligible womenHot flushesChronic treatmentReceptor antagonistGonadal steroidsLinzagolixAnalysis set
2021
Molecular mechanisms of estrogen action in female genital tract development
Alderman MH, Taylor HS. Molecular mechanisms of estrogen action in female genital tract development. Differentiation 2021, 118: 34-40. PMID: 33707128, PMCID: PMC8073215, DOI: 10.1016/j.diff.2021.01.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGene expressionSelective estrogen receptor modulatorsFemale genital tract developmentAberrant CpG methylationGenital tract developmentHistone modificationsEpigenetic regulationOrgan developmentCpG methylationTranscriptional pathwaysSpecific fetalEpigenetic modulationMolecular mechanismsFemale reproductive tractLate organogenesisHormonal regulationOrganogenesisEstrogen receptor modulatorsTract developmentReproductive tractIndependent fashionRegulationDisease statesEstrogen actionReceptor modulators
2020
Lessons from KEEPS: the Kronos Early Estrogen Prevention Study
Miller VM, Taylor HS, Naftolin F, Manson JE, Gleason CE, Brinton EA, Kling JM, Cedars MI, Dowling NM, Kantarci K, Harman SM. Lessons from KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric 2020, 24: 139-145. PMID: 32880220, PMCID: PMC8108428, DOI: 10.1080/13697137.2020.1804545.Peer-Reviewed Original ResearchConceptsKronos Early Estrogen Prevention StudyCarotid intima-medial thicknessPrevention StudyCardiovascular diseaseOral conjugated equine estrogenClinical CVD eventsUse of MHTOvert cardiovascular diseasePlacebo-controlled trialConjugated equine estrogensCoronary artery calciumIntima-medial thicknessMode of deliveryUptake of estrogensMood/anxietyAge-related increaseGenetic variantsCVD eventsAgatston unitsArtery calciumSymptom reliefPlacebo pillsEquine estrogensMenopausal womenMenopausal symptomsHeart fat and carotid artery atherosclerosis progression in recently menopausal women: impact of menopausal hormone therapy: The KEEPS trial.
El Khoudary SR, Venugopal V, Manson JE, Brooks MM, Santoro N, Black DM, Harman M, Naftolin F, Hodis H, Brinton E, Miller V, Taylor H, Budoff M. Heart fat and carotid artery atherosclerosis progression in recently menopausal women: impact of menopausal hormone therapy: The KEEPS trial. Menopause The Journal Of The North American Menopause Society 2020, 27: 255-262. PMID: 32015261, PMCID: PMC7113029, DOI: 10.1097/gme.0000000000001472.Peer-Reviewed Original ResearchConceptsCarotid intima-media thicknessEpicardial adipose tissueProgression of atherosclerosisCIMT progressionHormone therapyAtherosclerosis progressionMenopausal womenOral conjugated equine estrogenParacardial adipose tissue volumeMenopausal hormone therapyPlacebo-controlled trialConjugated equine estrogensFat depositionIntima-media thicknessMcg/dAdipose tissue volumeRoute of administrationPAT changesCEE administrationPlacebo groupEquine estrogensT-E2Fat accumulationMonth progressionO-CEE
2019
Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback
Kling JM, Dowling NM, Bimonte-Nelson HA, Gleason CE, Kantarci K, Manson JE, Taylor HS, Brinton EA, Lobo RA, Cedars MI, Pal L, Neal-Perry G, Naftolin F, Harman SM, Miller VM. Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback. AJP Regulatory Integrative And Comparative Physiology 2019, 317: r912-r920. PMID: 31663769, PMCID: PMC6957372, DOI: 10.1152/ajpregu.00234.2019.Peer-Reviewed Original ResearchConceptsFollicle-stimulating hormoneKronos Early Estrogen Prevention StudyHormone levelsHormone therapyT-E2Menopausal womenTreatment groupsOral conjugated equine estrogenCommon hormone therapiesPituitary-ovarian hormonesPostmenopausal hormone therapyActive treatment groupConjugated equine estrogensMo of treatmentDouble-blinded treatmentPlacebo groupEquine estrogensMenopausal transitionPrevention StudyO-CEEHormonal modulationBaseline levelsCognitive declinePlaceboHormone formulationsEffects of Hormone Therapy on Heart Fat and Coronary Artery Calcification Progression: Secondary Analysis From the KEEPS Trial
Khoudary S, Zhao Q, Venugopal V, Manson JE, Brooks MM, Santoro N, Black DM, Harman SM, Cedars MI, Hopkins PN, Kearns AE, Miller VM, Taylor HS, Budoff MJ. Effects of Hormone Therapy on Heart Fat and Coronary Artery Calcification Progression: Secondary Analysis From the KEEPS Trial. Journal Of The American Heart Association 2019, 8: e012763. PMID: 31652073, PMCID: PMC6761637, DOI: 10.1161/jaha.119.012763.Peer-Reviewed Original ResearchConceptsOral conjugated equine estrogenConjugated equine estrogensCoronary artery calcification (CAC) progressionBaseline CAC scoreEpicardial adipose tissueCAC scoreEquine estrogensMenopausal womenCAC progressionCalcification progressionAdipose tissueEpicardial adipose tissue accumulationEarly menopausal womenPlacebo-controlled trialAdipose tissue accumulationHormone therapy formulationsProgression of CACKEEP participantsHormone therapySubclinical atherosclerosisCAC measuresEndogenous estrogensFat accumulationTreatment groupsFat depots
2018
Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)
Cintron D, Lahr BD, Bailey KR, Santoro N, Lloyd R, Manson JE, Neal-Perry G, Pal L, Taylor HS, Wharton W, Naftolin F, Harman SM, Miller VM. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Menopause The Journal Of The North American Menopause Society 2018, 25: 145-153. PMID: 28832429, PMCID: PMC5771895, DOI: 10.1097/gme.0000000000000971.Peer-Reviewed Original ResearchConceptsKronos Early Estrogen Prevention StudyHormone therapyDomains of sleepSleep qualityDomain scoresMenopausal womenPrevention StudySleep domainsGlobal Pittsburgh Sleep Quality Index scoreOral conjugated equine estrogenPittsburgh Sleep Quality Index scorePittsburgh Sleep Quality IndexVasomotor symptom scoresConjugated equine estrogensSleep Quality IndexPoor sleep qualityGlobal sleep qualitySeverity of symptomsGlobal sleep scoreQuality Index scoresMenopausal hormonesVMS severityPostmenopausal womenVasomotor symptomsSpearman correlation coefficient
2017
Addition of Estradiol to Cross-Sex Testosterone Therapy Reduces Atherosclerosis Plaque Formation in Female ApoE−/− Mice
Goetz TG, Mamillapalli R, Sahin C, Majidi-Zolbin M, Ge G, Mani A, Taylor HS. Addition of Estradiol to Cross-Sex Testosterone Therapy Reduces Atherosclerosis Plaque Formation in Female ApoE−/− Mice. Endocrinology 2017, 159: 754-762. PMID: 29253190, PMCID: PMC5774248, DOI: 10.1210/en.2017-00884.Peer-Reviewed Original ResearchConceptsAtherosclerosis plaque formationLow-dose estradiolPlaque formationTestosterone therapyLesion progressionCross-sex hormone therapyEstradiol-treated miceLow-dose estrogenAtherosclerotic lesion progressionEffects of estrogenContribution of estradiolOil Red O stainAtherosclerosis lesion progressionAddition of estradiolWeeks of ageEstradiol therapyCardiovascular outcomesHormone therapyAortic sinusFemale ApoEAtherosclerosis progressionReduced atherosclerosisCombined therapyAortic archAtherosclerosis RiskEffects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS)
Taylor HS, Tal A, Pal L, Li F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Du W, Hodis HN, Lobo RA, Manson JE, Merriam GR, Miller VM, Naftolin F, Neal-Perry G, Santoro NF, Harman SM. Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Internal Medicine 2017, 177: 1471-1479. PMID: 28846767, PMCID: PMC5710212, DOI: 10.1001/jamainternmed.2017.3877.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultDouble-Blind MethodEstradiolEstrogen Replacement TherapyEstrogensEstrogens, Conjugated (USP)FemaleFollow-Up StudiesGlucuronatesHumansMiddle AgedPostmenopauseProgesteroneProgestinsProspective StudiesPsychiatric Status Rating ScalesQuality of LifeRisk FactorsSexual Dysfunction, PhysiologicalTime FactorsWomen's HealthConceptsKronos Early Estrogen Prevention StudyLow sexual functionTransdermal estrogen therapySexual functionAncillary studiesEstrogen therapyPostmenopausal womenPrevention StudyT-E2Female Sexual Function InventoryOral conjugated equine estrogenOverall scoreLower FSFI scoresEarly postmenopausal womenMenopausal hormone therapyPlacebo-controlled trialOral micronized progesteroneConjugated equine estrogensSexual Function InventoryLast menstrual periodEffects of OralQuality of lifeProportion of womenSymptoms of distressMicronized progesteroneSafety and benefit considerations for menopausal hormone therapy
Pickar JH, Archer DF, Kagan R, Pinkerton JV, Taylor HS. Safety and benefit considerations for menopausal hormone therapy. Expert Opinion On Drug Safety 2017, 16: 941-954. PMID: 28664754, DOI: 10.1080/14740338.2017.1343298.Peer-Reviewed Original ResearchConceptsSafety of HTConjugated equine estrogensHormone therapyEquine estrogensHealth initiativesDifferent estrogensEstrogen-progestogen therapyMenopausal hormone therapyUnexpected safety concernsWomen's Health InitiativeRoute of administrationHT initiationEffect of ageSafety profileDifferent progestogensCardiovascular diseaseObservational studySynthetic progestinsAdministration routeEstrogenTherapyClinical useSafety evidenceRegimensFurther studiesBisphenol-A exposure in utero programs a sexually dimorphic estrogenic state of hepatic metabolic gene expression
Ilagan Y, Mamillapalli R, Goetz L, Kayani J, Taylor HS. Bisphenol-A exposure in utero programs a sexually dimorphic estrogenic state of hepatic metabolic gene expression. Reproductive Toxicology 2017, 71: 84-94. PMID: 28476547, DOI: 10.1016/j.reprotox.2017.05.001.Peer-Reviewed Original ResearchConceptsBPA exposureGene expressionAdult gene expressionFetal BPA exposureBisphenol A (BPA) exposureMetabolic gene expressionEstrogen receptor alphaExpression of genesBeta gene expressionEstrogenic stateEstrogen treatmentPregnant miceMetabolic disordersE2 stimulationReceptor alphaFetal developmentLipid metabolismDay 9Developmental programmingSexual dimorphismFemale offspringLiverObesityGenesAdult responsesPartial suppression of estradiol: a new strategy in endometriosis management?
Donnez J, Taylor RN, Taylor HS. Partial suppression of estradiol: a new strategy in endometriosis management? Fertility And Sterility 2017, 107: 568-570. PMID: 28259257, DOI: 10.1016/j.fertnstert.2017.01.013.Peer-Reviewed Original ResearchLongitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo
Santoro N, Allshouse A, Neal-Perry G, Pal L, Lobo RA, Naftolin F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Dowling NM, Dunn M, Gleason CE, Hodis HN, Isaac B, Magnani M, Manson JE, Miller VM, Taylor HS, Wharton W, Wolff E, Zepeda V, Harman SM. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo. Menopause The Journal Of The North American Menopause Society 2017, 24: 238-246. PMID: 27779568, PMCID: PMC5323337, DOI: 10.1097/gme.0000000000000756.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultAutonomic Nervous System DiseasesDrug Therapy, CombinationEstradiolEstrogen Replacement TherapyEstrogensEstrogens, Conjugated (USP)FemaleHot FlashesHumansIrritable MoodLongitudinal StudiesMiddle AgedPostmenopauseProgesteroneProgestinsSleep Initiation and Maintenance DisordersTreatment OutcomeVasomotor SystemConceptsOral conjugated estrogensActive treatment armsBody mass indexTreatment armsRace/ethnicityMonths postrandomizationNight sweatsPostmenopausal womenHot flashesMass indexMenopausal symptomsConjugated estrogensEarly postmenopausal womenMenopausal hormone therapyFinal menstrual periodProportion of womenHormone regimensTransdermal estradiolTransdermal estrogenHormone therapyVasomotor symptomsSymptom reliefTreat analysisActive treatmentConventional doses
2016
Effects of hormones on skin wrinkles and rigidity vary by race/ethnicity: four-year follow-up from the ancillary skin study of the Kronos Early Estrogen Prevention Study
Owen CM, Pal L, Mumford SL, Freeman R, Isaac B, McDonald L, Santoro N, Taylor HS, Wolff EF. Effects of hormones on skin wrinkles and rigidity vary by race/ethnicity: four-year follow-up from the ancillary skin study of the Kronos Early Estrogen Prevention Study. Fertility And Sterility 2016, 106: 1170-1175.e3. PMID: 27393520, DOI: 10.1016/j.fertnstert.2016.06.023.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAdultBlack or African AmericanDouble-Blind MethodDrug CombinationsElasticityEstradiolEstrogen Replacement TherapyEstrogens, Conjugated (USP)FemaleHumansMenopauseMiddle AgedProgesteroneSkinSkin AgingTime FactorsTransdermal PatchTreatment OutcomeUnited StatesWhite PeopleConceptsKronos Early Estrogen Prevention StudyConjugated equine estrogensHormone therapyRace/ethnicityRigidity scoresSkin wrinklesPrevention StudyOral conjugated equine estrogenWhite womenLowest wrinkle scoresPlacebo-controlled trialLast menstrual periodAcademic medical centerBlack womenWrinkle scoreEffects of hormonesEquine estrogensMenopausal womenMenstrual periodMedical CenterMAIN OUTCOMESkin rigidityWomenPlaceboScoresAromatase inhibitor regulates let-7 expression and let-7f–induced cell migration in endometrial cells from women with endometriosis
Cho S, Mutlu L, Zhou Y, Taylor HS. Aromatase inhibitor regulates let-7 expression and let-7f–induced cell migration in endometrial cells from women with endometriosis. Fertility And Sterility 2016, 106: 673-680. PMID: 27320036, PMCID: PMC5831184, DOI: 10.1016/j.fertnstert.2016.05.020.Peer-Reviewed Original ResearchConceptsHuman endometrial stromal cellsLet-7f mimicIshikawa cellsL treatment groupEndometrial cellsAromatase expressionTreatment groupsEndometrial stromal cellsAromatase inhibitor treatmentPathogenesis of endometriosisLet-7f expressionSignificant differencesDose-dependent mannerLetrozole treatmentModulation of microRNAsAromatase inhibitorsLaparoscopic surgeryMAIN OUTCOMEAI treatmentEndometriosisLetrozole concentrationsTherapeutic levelsInhibitor treatmentControl groupTherapeutic potentialBisphenol A (BPA) Exposure In Utero Leads to Immunoregulatory Cytokine Dysregulation in the Mouse Mammary Gland: A Potential Mechanism Programming Breast Cancer Risk
Fischer C, Mamillapalli R, Goetz T, Jorgenson E, Ilagan Y, Taylor HS. Bisphenol A (BPA) Exposure In Utero Leads to Immunoregulatory Cytokine Dysregulation in the Mouse Mammary Gland: A Potential Mechanism Programming Breast Cancer Risk. Discover Oncology 2016, 7: 241-251. PMID: 26911702, PMCID: PMC10726733, DOI: 10.1007/s12672-016-0254-5.Peer-Reviewed Original ResearchConceptsBPA exposureBreast cancerAdaptive immunityMammary glandPosterior mammary glandsTh1 T cellsAberrant immune responseAbnormal mammary gland developmentHuman breast cancerPossible environmental etiologyInterleukin-1 gene familyMammary gland developmentMouse mammary tissueCytolytic CD8Osmotic minipumpsCD1 miceT cellsImmune responseGene familyExpression of membersCXC familyMammary tissueDevelopmental programmingUteroWestern blot
2015
Peripheral Microvascular Vasodilatory Response to Estradiol and Genistein in Women with Insulin Resistance
Wenner MM, Taylor HS, Stachenfeld NS. Peripheral Microvascular Vasodilatory Response to Estradiol and Genistein in Women with Insulin Resistance. Microcirculation 2015, 22: 391-399. PMID: 25996650, PMCID: PMC4506724, DOI: 10.1111/micc.12208.Peer-Reviewed Original ResearchConceptsL-NMMAMicrovascular vasodilationHealthy womenVasodilatory responsivenessLocal cutaneous heatingMicrovascular vasodilatory functionMicrovascular vasodilatory responsesBeat blood pressureHealthy young womenLaser Doppler flowmetryHeat-induced vasodilationMicrovascular responsivenessVascular effectsVasodilatory responseBlood pressureMicrovascular functionVasodilatory functionCutaneous heatingInsulin resistanceCutaneous circulationDoppler flowmetryGEN exposureInteraction of E2VasodilationMicrodialysis perfusionEffects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study
Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, Brinton EA, Cedars MI, Lobo RA, Merriam GR, Neal-Perry G, Santoro NF, Taylor HS, Black DM, Budoff MJ, Hodis HN, Naftolin F, Harman SM, Asthana S. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study. PLOS Medicine 2015, 12: e1001833. PMID: 26035291, PMCID: PMC4452757, DOI: 10.1371/journal.pmed.1001833.Peer-Reviewed Original ResearchConceptsCognitive outcomesMood outcomesVerbal learning/memoryAttention/executive functionEffect sizeAuditory attention/Kronos Early Estrogen Prevention StudyAffective studiesLearning/memoryModified Mini-Mental State ExaminationMenopausal hormone therapyMedium effect sizeMini-Mental State ExaminationTreatment-related benefitsAttention/Cognitive factorsMental flexibilityExecutive functionMood measuresMood effectsAnxiety symptomsAge 65 y.Beneficial mood effectsCognitive AssessmentMood statesChemoattraction of bone marrow-derived stem cells towards human endometrial stromal cells is mediated by estradiol regulated CXCL12 and CXCR4 expression
Wang X, Mamillapalli R, Mutlu L, Du H, Taylor HS. Chemoattraction of bone marrow-derived stem cells towards human endometrial stromal cells is mediated by estradiol regulated CXCL12 and CXCR4 expression. Stem Cell Research 2015, 15: 14-22. PMID: 25957946, PMCID: PMC5001152, DOI: 10.1016/j.scr.2015.04.004.Peer-Reviewed Original ResearchConceptsHuman endometrial stromal cellsBone marrow cellsEndometrial stromal cellsCXCR4 expressionEndometrial cellsBM cellsCXCL12/CXCR4 expressionStromal cellsBone marrow-derived stem cellsMarrow-derived stem cellsHuman endometrial cellsStem cellsEndometrial disordersCXCL12 receptorCXCR4 antagonistCXCL12 expressionChemokine CXCL12Uterine endometriumCells engraftBone marrowEndometriumMarrow cellsStem cell migrationCXCR4CXCL12
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply